Physician profile
Peter Ells
NPI 1336174143
$81,282.28
in general payments reported to CMS, 2019-2025
18 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $6,585 · 2021: $7,855 · 2022: $15K · 2023: $14K · 2024: $11K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $4,820 · Food and Beverage: $4,702 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,160.00 |
| Travel and Lodging | $4,819.85 |
| Food and Beverage | $4,702.09 |
| Education | $106.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $72,935.49 | 2019-2025 | Epclusa |
| Intercept Pharmaceuticals, INC. | $4,290.78 | 2019-2025 | Ocaliva |
| Abbvie INC. | $1,585.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.77 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $361.49 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $234.91 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $206.71 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $176.71 | 2019-2025 | Entyvio, Gattex |
| Conmed Corporation | $130.46 | 2022 | |
| Ardelyx, INC. | $124.76 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $121.84 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $112.41 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $111.57 | 2019-2024 | |
| Genzyme Corporation | $100.92 | 2024-2025 | |
| Celltrion USA INC. | $44.32 | 2024-2025 | Zymfentra, Vegzelma |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.56 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $21.23 | 2023 | Sutab |
| Pfizer INC. | $15.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.